Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor SALT LAKE CITY, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Navigen, Inc. announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug application ("IND") for...